Evidence map›Paper›PMID 39593733›Full record

ArticleBioengineering (Basel, Switzerland)2024

RMCNet: A Liver Cancer Segmentation Network Based on 3D Multi-Scale Convolution, Attention, and Residual Path.

Zerui Zhang, Jianyun Gao, Shu Li, Hao Wang

Abstract read
In one paragraph

Article in Bioengineering (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zerui ZhangSchool of Bioengineering, Chongqing University, Chongqing 400044, China.
Jianyun GaoMedical Device Institute, Shenyang Pharmaceutical University, Benxi 117004, China.ORCID 0009-0009-0656-3123
Shu LiInstitute for Medical Device Control, National Institutes for Food and Drug Control, Beijing 102629, China.
Hao WangInstitute for Medical Device Control, National Institutes for Food and Drug Control, Beijing 102629, China.ORCID 0000-0003-4094-7306

Funding

National Institutes for Food and Drug Control key technology funding GJJS-2022-3-1
6 · The paper itself

Abstract

Abdominal CT images are important clues for diagnosing liver cancer lesions. However, liver cancer presents challenges such as significant differences in tumor size, shape, and location, which can affect segmentation accuracy. To address these challenges, we propose an end-to-end 3D segmentation algorithm, RMCNet. In the shallow encoding part of RMCNet, we incorporated a 3D multiscale convolution (3D-Multiscale Convolution) module to more effectively extract tumors of varying sizes. Moreover, the convolutional block attention module (CBAM) is used in the encoding part to help the model focus on both the shape and location of tumors. Additionally, a residual path is introduced in each encoding layer to further enrich the extracted feature maps. Our method achieved DSC scores of 76.56% and 72.96%, JCC scores of 75.82% and 71.25%, HD values of 11.07 mm and 17.06 mm, and ASD values of 2.54 mm and 10.51 mm on the MICCAI 2017 Liver Tumor Segmentation public dataset and the 3Dircadb-01 public dataset, respectively. Compared to other methods, RMCNet demonstrates superior segmentation performance and stronger generalization capability.

Indexed as

3D liver cancer segmentation3D multi-scale convolutionattention moduleresidual path

Identifiers

PMID39593733
PMCPMC11591158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.